Cao Minsong, Gao Yu, Yoon Stephanie M, Yang Yingli, Sheng Ke, Ballas Leslie K, Basehart Vincent, Sachdeva Ankush, Felix Carol, Low Daniel A, Steinberg Michael L, Kishan Amar U
Department of Radiation Oncology, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA.
Department of Radiation Oncology, University of Southern California, Los Angeles, CA 90089, USA.
Cancers (Basel). 2021 Jun 4;13(11):2802. doi: 10.3390/cancers13112802.
To evaluate geometric variations of patients receiving stereotactic body radiotherapy (SBRT) after radical prostatectomy and the dosimetric benefits of stereotactic MRI guided adaptive radiotherapy (SMART) to compensate for these variations.
MATERIALS/METHODS: The CTV and OAR were contoured on 55 MRI setup scans of 11 patients treated with an MR-LINAC and enrolled in a phase II trial of post-prostatectomy SBRT. All patients followed institutional bladder and rectum preparation protocols and received five fractions of 6-6.8 Gy to the prostate bed. Interfractional changes in volume were calculated and shape deformation was quantified by the Dice similar coefficient (DSC). Changes in CTV-V95%, bladder and rectum maximum dose, V32.5Gy and V27.5Gy were predicted by recalculating the initial plan on daily MRI. SMART was retrospectively simulated if the predicted dose exceeded pre-set criteria.
The CTV volume and shape remained stable with a median volumetric change of 3.0% (IQR -3.0% to 11.5%) and DSC of 0.83 (IQR 0.79 to 0.88). Relatively large volumetric changes in bladder (median -24.5%, IQR -34.6% to 14.5%) and rectum (median 5.4%, IQR - 9.7% to 20.7%) were observed while shape changes were moderate (median DSC of 0.79 and 0.73, respectively). The median CTV-V95% was 98.4% (IQR 94.9% to 99.6%) for the predicted doses. However, SMART would have been deemed beneficial for 78.2% of the 55 fractions based on target undercoverage (16.4%), exceeding OAR constraints (50.9%), or both (10.9%). Simulated SMART improved the dosimetry and met dosimetric criteria in all fractions. Moderate correlations were observed between the CTV-V95% and target DSC (R2 = 0.73) and bladder mean dose versus volumetric changes (R2 = 0.61).
Interfractional dosimetric variations resulting from anatomic deformation are commonly encountered with post-prostatectomy RT and can be mitigated with SMART.
评估根治性前列腺切除术后接受立体定向体部放疗(SBRT)患者的几何变化,以及立体定向MRI引导的自适应放疗(SMART)对补偿这些变化的剂量学益处。
材料/方法:在11例接受MR-LINAC治疗并参加前列腺切除术后SBRT II期试验的患者的55次MRI定位扫描上勾画临床靶区(CTV)和危及器官(OAR)。所有患者均遵循机构膀胱和直肠准备方案,接受5次分割,每次6 - 6.8 Gy照射前列腺床。计算分次间体积变化,并通过骰子相似系数(DSC)量化形状变形。通过在每日MRI上重新计算初始计划来预测CTV-V95%、膀胱和直肠最大剂量、V32.5Gy和V27.5Gy的变化。如果预测剂量超过预设标准,则对SMART进行回顾性模拟。
CTV体积和形状保持稳定,体积变化中位数为3.0%(四分位间距-3.0%至11.5%),DSC为0.83(四分位间距0.79至0.88)。观察到膀胱(中位数-24.5%,四分位间距-34.6%至14.5%)和直肠(中位数5.4%,四分位间距-9.7%至20.7%)有相对较大的体积变化,而形状变化适中(中位数DSC分别为0.79和0.73)。预测剂量的CTV-V95%中位数为98.4%(四分位间距94.9%至99.6%)。然而,基于靶区覆盖不足(16.4%)、超过OAR限制(50.9%)或两者兼有(10.9%),SMART对55次分割中的78.2%被认为是有益的。模拟的SMART改善了剂量学并在所有分割中满足剂量学标准。观察到CTV-V95%与靶区DSC(R2 = 0.73)以及膀胱平均剂量与体积变化(R2 = 0.61)之间存在中度相关性。
前列腺切除术后放疗中常见因解剖变形导致的分次间剂量学变化,SMART可减轻这种变化。